Acoramidis Cardiorenal Posthoc Signal: Differentiation Claim Meets Payer Equivalence Verdict

BridgeBio's Attruby Shows Kidney Protection in ATTR-CM

BridgeBio's protein stabilizing therapy, Attruby, demonstrated significant kidney-protective benefits in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), according to a recent posthoc analysis. This evaluation, drawing data from a Phase 2 study and the Phase 3 ATTRibute-CM trial (which led to the drug's November 2024 approval), revealed sustained and significant placebo-adjusted improvements in estimated glomerular filtration rate (eGFR) slope at 30 months, following an initial reversible dip. Additionally, Attruby showed sustained reductions in urinary albumin-to-creatinine ratio, indicating direct kidney-protective effects. Analysts at Jefferies highlighted these "cardiorenal protective benefits" as a key differentiator for Attruby in the competitive ATTR-CM market.

• The posthoc analysis of Attruby's Phase 2 and Phase 3 ATTRibute-CM trial data revealed compelling evidence of kidney protection. Patients treated with Attruby experienced an initial, reversible decrease in estimated glomerular filtration rate (eGFR), followed by sustained and significant placebo-adjusted improvements in eGFR slope at 30 months. This suggests direct kidney-protective effects. Furthermore, the analysis documented significant and sustained reductions in urinary albumin-to-creatinine ratio, a crucial indicator of kidney damage, reinforcing the drug's beneficial impact on renal health.
• Attruby's demonstrated cardiorenal protective benefits are seen as a significant differentiator in the crowded transthyretin amyloidosis cardiomyopathy (ATTR-CM) market. Analysts from Jefferies noted that these effects appear "distinct" from other therapies, including Pfizer's Vyndaqel/Vyndamax, which generated $6.4 billion in worldwide sales last year. This unique kidney function preservation could provide BridgeBio with a competitive edge, potentially improving hospitalization and mortality outcomes for patients and strengthening Attruby's position against existing and emerging treatments like AstraZeneca and Ionis' Wainua.
• The findings stem from a posthoc analysis that integrated data from a Phase 2 study and the pivotal Phase 3 ATTRibute-CM trial, which previously supported Attruby's approval in November 2024. Jefferies expressed a positive outlook, stating that the assessments "point to cardiorenal protective benefits" and that the degree of kidney function protection "looks competitive to kidney-targeted therapies." This expert endorsement underscores the clinical significance of the data, suggesting that slowing kidney progression could lead to improved patient outcomes and market success for BridgeBio.

Addressing Unmet Needs in ATTR-CM Beyond Cardiac Function

Current treatment approaches for ATTR-CM face a convergence of clinical, diagnostic, and systemic challenges that limit optimal patient outcomes. While agents such as tafamidis have demonstrated meaningful efficacy, significant gaps remain across the continuum of care — from initial disease recognition through long-term disease modification.

• Underdiagnosis and delayed recognition: ATTR-CM is a progressive infiltrative cardiomyopathy that closely mimics hypertensive and hypertrophic heart disease, contributing to chronic underdiagnosis — particularly in wild-type disease. Broader clinical awareness of its prevalence, symptom profile, and available diagnostic tools is essential for timely identification in patients presenting with left ventricular hypertrophy.

• Access and eligibility barriers: Tafamidis reimbursement eligibility may exclude patients with persistent systolic dysfunction (e.g., LVEF ~43%), limiting access for a clinically meaningful subset. Compounding this, conventional heart failure therapies are frequently poorly tolerated in ATTR-CM patients, narrowing the overall management toolkit.

• Disease-modifying limitations of current stabilizers: TTR stabilizers such as tafamidis and acoramidis prevent further disease progression but do not reverse existing amyloid burden. Similarly, as of 2020, the long-term cardiac impact of agents targeting hepatic TTR production had not been established in cardiomyopathy populations.

• Treatment timing dependency: Available therapies demonstrate greater efficacy when initiated in the early stages of disease. As earlier diagnosis becomes more common and trial populations trend toward milder disease at enrollment, effect sizes in future clinical studies are expected to be smaller than those observed in historical trials.

• Prohibitive cost and healthcare system burden: Tafamidis is priced at approximately $225,000 per year — the most expensive cardiovascular drug launched in the United States as of 2021. Cost-effectiveness analyses project an incremental cost-effectiveness ratio of approximately $880,000 per quality-adjusted life-year, requiring a price reduction of ~92.6% (to ~$16,563/year) to meet a $100,000/QALY threshold. Treating all eligible U.S. patients (estimated at 120,000) is projected to increase annual healthcare spending by $32.3 billion.

• Evolving and incompletely defined treatment goals: Evidence-based guidance in this space continues to mature, with treatment goals still evolving. Unmet needs persist — particularly in patients with systolic dysfunction — underscoring the need for continued development of clinical frameworks and novel therapeutic strategies.

Attruby's Cardiorenal Protection: Key Findings from Posthoc Analysis

The ATTR-CM clinical trial landscape has evolved substantially over the past decade, encompassing multiple phase 3 RCTs that differ in enrollment period, patient population, and trial eligibility stringency. A systematic review of 58 publications across 13 clinical trials (enrollment 2008–2022) documents a clear temporal trend: placebo-arm all-cause mortality (ACM) at 12 months declined progressively across successive trials, reflecting earlier patient identification driven by advances in diagnostics and the availability of disease-modifying therapies. When the eligibility criteria of five major phase 3 trials were applied retrospectively to a real-world ATTR-CM cohort of 353 patients (median age 80.3 years; 17.6% female) from the Medical University of Vienna (March 2012–May 2024), meaningful differences in trial reach and enrolled disease severity were observed.

Key baseline characteristics assessed across trials included proportion of participants with variant ATTR-CM, NYHA functional class, NT-proBNP and troponin levels, and eGFR — all of which varied systematically by enrollment year. Notably, DEPLETTR-CM was the only trial whose criteria would have selected a meaningfully distinct, higher-acuity subgroup relative to the broader real-world population, while ATTRIBUTE, ATTRACT, HELIOS-B, and CARDIO-TTRANSFORM cohorts demonstrated only minor baseline differences from one another and from the real-world comparator.

Positioning Attruby in the Evolving ATTR-CM Treatment Landscape

The treatment landscape for transthyretin amyloidosis cardiomyopathy (ATTR-CM) has undergone substantial transformation over the past five years, anchored by long-term evidence consolidating tafamidis as the foundational standard of care. The pivotal ATTR-ACT long-term extension study, with a median follow-up of 58.5 months in the continuous tafamidis arm (n=176), demonstrated 79 deaths (44.9%) versus 111 deaths (62.7%) in the placebo-to-tafamidis group (HR 0.59; 95% CI 0.44–0.79; P<0.001). Mortality benefits were consistent across both variant and wild-type ATTR-CM subgroups (HR 0.57 and 0.61, respectively) and across NYHA functional classes, with the greatest absolute benefit observed in class I/II patients (HR 0.56; P=0.003). A subsequent NAC staging analysis — extending follow-up to 90 months — further demonstrated that survival curve divergence occurred earliest in stage I patients, reinforcing the clinical imperative of early diagnosis and prompt treatment initiation. Post-hoc analyses confirmed that tafamidis-treated patients exhibited significantly higher odds of improvement across functional and biomarker endpoints at 30 months, including 6-minute walk distance (OR 4.9), KCCQ-OS score (OR 3.3), and NT-proBNP (OR 5.3; all P<0.001). Real-world evidence from THAOS, a Japanese single-centre cohort, and a 2025 meta-analysis of seven studies (OR for mortality 0.55; 95% CI 0.42–0.73; I²=41%; P<0.0001) collectively corroborate the trial findings across diverse patient populations.

The approval of acoramidis in 2024 — across the FDA, EMA, and additional regulatory jurisdictions — marked the most significant expansion of the ATTR-CM therapeutic armamentarium since tafamidis. As a next-generation TTR super-stabilizer achieving ≥90% TTR stabilization through enthalpic, hydrogen bond-based binding at the thyroxine-binding site, acoramidis demonstrated compelling efficacy in the ATTRibute-CM phase 3 trial (n=611). A significantly higher proportion of acoramidis-treated patients achieved clinically meaningful improvement in NT-proBNP or 6-minute walk distance versus placebo (22.7% vs. 8.9%; OR 3.0; 95% CI 1.8–5.1; P<0.001), and the agent reduced the risk of first outpatient worsening heart failure by 41% (HR 0.59; 95% CI 0.46–0.75), with Kaplan–Meier curve separation evident as early as day 30. Beyond TTR stabilization, the pipeline has expanded to include TTR-silencing agents — patisiran, vutrisiran, and eplontersen — as well as CRISPR-Cas9-based gene silencing (NTLA-2001) and investigational anti-amyloid therapies targeting existing fibril deposits, the latter being particularly relevant for patients presenting with advanced disease and substantial amyloid burden.

Emerging real-world and observational data have also begun to define the role of adjunctive strategies. SGLT2 inhibitors combined with tafamidis demonstrated significantly lower all-cause hospitalizations at one and three years (OR 0.67; P=0.005 and P=0.006, respectively) and reduced acute myocardial infarction events (1-year OR 0.44; P=0.001) in propensity score-matched cohorts of 409 patients each, though no statistically significant mortality reduction was observed. A separate wild-type ATTR-CM cohort study (n=623 matched patients) similarly showed SGLT2 inhibitor monotherapy associated with reduced heart failure exacerbations (HR 0.64; 95% CI 0.48–0.86), all-cause hospitalizations (HR 0.72), and acute kidney injury (HR 0.53), with a non-significant trend toward mortality reduction (HR 0.83; P=0.165). Across all these data, consistent predictors of attenuated treatment benefit — including advanced NYHA class, elevated NT-proBNP and troponin T, older age, and markers of right ventricular dysfunction — highlight that disease stage at treatment initiation remains a critical determinant of long-term outcomes, a theme that will continue to shape both trial design and clinical decision-making as the field matures.

Attruby's Renal Edge: Differentiating ATTR-CM Care

The recent post-hoc analysis highlighting Attruby's kidney-protective benefits offers a compelling new narrative in the evolving treatment landscape for transthyretin amyloid cardiomyopathy (ATTR-CM). This progressive, life-threatening disease, characterized by misfolded transthyretin protein deposition, impacts not only the heart but also other vital organs, including the kidneys. While acoramidis, a potent transthyretin stabilizer, has already demonstrated significant improvements in cardiac outcomes, mortality, and quality of life, the sustained improvements in estimated glomerular filtration rate (eGFR) slope and reductions in urinary albumin-to-creatinine ratio underscore its potential for more comprehensive multi-organ protection.

This finding strategically positions Attruby as a differentiated option, particularly for ATTR-CM patients with existing renal impairment or those at risk of developing it. In a market where tafamidis is well-established and gene-silencing therapies like vutrisiran are gaining traction, a clear advantage in multi-organ protection could be a powerful driver for adoption. However, it is crucial to acknowledge that these renal benefits stem from a post-hoc analysis. While promising, prospective studies would further solidify these findings and their impact on long-term patient management.

Furthermore, the high cost of disease-modifying ATTR-CM therapies, including acoramidis, remains a significant barrier to access in many healthcare systems. Even with enhanced clinical benefits, affordability challenges could limit widespread uptake. Competitors may also seek to demonstrate similar multi-organ benefits, potentially eroding Attruby's unique selling proposition over time. Ultimately, this new data emphasizes the shift towards more holistic ATTR-CM management, where therapies offering broad systemic benefits will be increasingly valued. Future research will likely focus on comparative effectiveness and personalized treatment strategies to optimize outcomes for this complex patient population.